Related Experiment Video
Updated: Apr 17, 2026
07:46
Assessing Endothelial Vasodilator Function with the Endo-PAT 2000
Published on: October 15, 2010
44.7K
Genetic polymorphisms and endothelial dysfunction in patients with essential hypertension: a cross-sectional
Summary
Essential hypertension is linked to endothelial dysfunction, but this study found no association between common gene polymorphisms (ecNOS, ACE, AT1R) and hypertension or dysfunction. These complex conditions are likely multicausal.
Area of Science:
- Cardiovascular Genetics
- Molecular Medicine
- Hypertension Research
Background:
- Endothelial dysfunction is implicated in hypertension development, with associations noted for endothelial constitutive nitric oxide synthase (ecNOS) gene polymorphism.
- Genes in the renin-angiotensin system, such as angiotensin-converting enzyme (ACE) and angiotensin II type 1 receptor (ATIR), are linked to essential hypertension, but their role in endothelial dysfunction remains unclear.
Purpose of the Study:
- To investigate the presence of genetic polymorphisms and endothelial dysfunction in patients with essential hypertension.
- To determine the impact of specific gene polymorphisms on endothelial function in hypertensive individuals.
Main Methods:
- Analyzed ecNOS, ACE, and AT1R gene polymorphisms in 129 essential hypertension patients and 129 controls using polymerase chain reaction.
- Assessed endothelial function via brachial artery vasodilation using high-resolution ultrasound.
- Employed univariate and multivariate analyses, including correlation coefficients and logistic regression, to evaluate relationships.
Main Results:
- A significant difference in endothelium-dependent vasodilation was observed between hypertensive patients and controls (16% difference, p<0.02).
- No significant differences in the prevalence of ecNOS, ACE, or AT1R gene polymorphisms were found between patients and controls.
- No statistically significant correlations were identified between endothelial function and the genotypes of these three genes in either group.
Conclusions:
- Established a significant link between endothelial dysfunction and essential hypertension.
- Did not find associations between the studied genetic markers and essential hypertension, nor between endothelial dysfunction and these genetic markers.
- Suggests that endothelial dysfunction and hypertension are complex, multicausal disorders, potentially influenced by other genetic factors or confounders.
Related Concept Videos
01:29Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu
132
Genetic variations significantly influence drug response through pharmacokinetics, receptor interactions, and biologic milieu modifications. Pharmacokinetic alterations impact drug metabolism and clearance, affecting efficacy and toxicity. Variants in drug-metabolizing enzymes, such as CYP2C9 and CYP2C19, alter drug activation and elimination. For example, CYP2C9 loss-of-function variants require lower warfarin doses to prevent excessive bleeding, while CYP2C19 variants reduce clopidogrel...
132
01:11Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase
72
Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
72
01:27Pharmacogenetics of Drug Metabolism: Overview
157
Genetic polymorphism in drug metabolism is crucial to the inter-individual variability observed in drug responses. Drug metabolism primarily involves the chemical modification of drugs and other xenobiotics to enhance their elimination by increasing their polarity. Two main classes of enzymes mediate this biotransformation process: Phase I enzymes, primarily cytochrome P450s, catalyze oxidation and reduction reactions, while other enzymes, such as esterases, mediate hydrolysis, and Phase II...
157
01:27Principles of Pharmacogenetics: Types of Genetic Variants
119
The human genome is over 99.9% identical between individuals, yet genetic differences exist at millions of bases. The human genome contains approximately 3 million variant positions per individual, many of which are heterozygous, contributing to genetic diversity and individual traits. Genetic variations include single-nucleotide polymorphisms (SNPs), insertions, deletions, and copy number variations (CNVs).SNPs, the most common variation, involve single-base changes in DNA. These can be...
119
01:29Pharmacogenomics: Identification of New Drug Targets
95
Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...
95
01:18Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists
577
Endothelins (ETs) are potent vasoactive peptides critical in the human body's various physiological and pathological processes. One of the most promising therapeutic strategies for treating pulmonary arterial hypertension (PAH) involves counteracting the effects of these endothelins using a class of drugs known as endothelin receptor antagonists.
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...
577